[{"orgOrder":0,"company":"Acousia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hearing Loss Company Acousia Therapeutics: First Patient With Age-related Hearing Loss Treated With ACOU085","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I"},{"orgOrder":0,"company":"Acousia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acousia Therapeutics to Present Its First-in-class Hearing Loss Treatment Program With ACOU085 at the 2nd Inner Ear Therapeutics Summit in Boston","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I"},{"orgOrder":0,"company":"Acousia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hearing Loss Company Acousia Therapeutics to Present Data for Lead Candidates ACOU085 & ACOU082 at ARO 2023 Mid Winter Meeting February 11-15","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Acousia Therapeutics
ACOU085 is a proprietary small molecule, etiology-agnostic otoprotective drug candidate, expected to finish a first-in-man clinical Phase 1b study by late 2022 using standard transtympanic administration of a slow-release gel formulation.
ACOU085 is a proprietary, first-in-class, small-molecule otoprotective drug candidate, which is currently being tested in a Phase 1b clinical trial involving age-related hearing loss (ARHL) patients.
ACOU085 is a proprietary small-molecule, otoprotective drug candidate that modulates a well-defined molecular target preferentially expressed in the sensory cells of the inner ear, the so-called outer hair cells (OHC).